文献速递肝病

ADAMTSL2蛋白及可溶性生物标志物组合可识别NAFLD高危NASH和纤维化

ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
PubMed 文献 · J Hepatol · 2021-10-01

该研究通过适配体蛋白质组学在多个队列中筛选与NAFLD纤维化相关的循环蛋白,发现ADAMTSL2蛋白及8蛋白组合能准确区分高危NASH和显著纤维化,其诊断性能优于NAFLD纤维化评分和FIB-4评分。

要点

  • ADAMTSL2蛋白可区分NAFL/NASH F0-1与高危NASH,C、D队列AUROC分别为0.83和0.86。
  • 8蛋白组合区分NAFL/NASH F0-1与高危NASH的AUROC在C、D队列分别为0.90和0.87。
  • ADAMTSL2和8蛋白组合诊断性能优于NAFLD纤维化评分和FIB-4评分。

核心结论

  • ADAMTSL2蛋白和8蛋白可溶性标志物组合与高危NASH及显著纤维化高度相关,诊断性能优于标准纤维化评分。

研究设计与样本

  • 研究采用适配体蛋白质组学在队列A(n=62)和B(n=98)中测量4783种蛋白,并在队列C(n=71)和D(n=84)中验证。

主要发现

  • 在队列A和B中,16种蛋白随纤维化程度差异显著。
  • ADAMTSL2区分NAFL/NASH F0-1与高危NASH的AUROC在队列C和D分别为0.83和0.86。
  • ADAMTSL2区分NAFL/NASH F0-1与NASH F2-3的AUROC在队列C和D分别为0.80和0.83。
  • 8蛋白组合区分NAFL/NASH F0-1与高危NASH的AUROC在队列C和D分别为0.90和0.87。
  • 8蛋白组合区分NAFL/NASH F0-1与NASH F2-3的AUROC在队列C和D分别为0.89和0.83。

临床怎么用

  • ADAMTSL2蛋白和8蛋白组合可作为无创诊断工具,辅助识别NAFLD患者中的高危NASH和显著纤维化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Identifying fibrosis in non-alcoholic fatty liver disease (NAFLD) is essential to predict liver-related outcomes and guide treatment decisions. A protein-based signature of fibrosis could serve as a valuable, non-invasive diagnostic tool. This study sought to identify circulating proteins associated with fibrosis in NAFLD. METHODS: We used aptamer-based proteomics to measure 4,783 proteins in 2 cohorts (Cohort A and B). Targeted, quantitative assays coupling aptamer-based protein pull down and mass spectrometry (SPMS) validated the profiling results in a bariatric and NAFLD cohort (Cohort C and D, respectively). Generalized linear modeling-logistic regression assessed the ability of candidate proteins to classify fibrosis. RESULTS: From the multiplex profiling, 16 proteins differed significantly by fibrosis in cohorts A (n = 62) and B (n = 98). Quantitative and robust SPMS assays were developed for 8 proteins and validated in Cohorts C (n = 71) and D (n = 84). The A disintegrin and metalloproteinase with thrombospondin motifs like 2 (ADAMTSL2) protein accurately distinguished non-alcoholic fatty liver (NAFL)/non-alcoholic steatohepatitis (NASH) with fibrosis stage 0-1 (F0-1) from at-risk NASH with fibrosis stage 2-4, with AUROCs of 0.83 and 0.86 in Cohorts C and D, respectively, and from NASH with significant fibrosis (F2-3), with AUROCs of 0.80 and 0.83 in Cohorts C and D, respectively. An 8-protein panel distinguished NAFL/NASH F0-1 from at-risk NASH (AUROCs 0.90 and 0.87 in Cohort C and D, respectively) and NASH F2-3 (AUROCs 0.89 and 0.83 in Cohorts C and D, respectively). The 8-protein panel and ADAMTSL2 protein had superior performance to the NAFLD fibrosis score and fibrosis-4 score. CONCLUSION: The ADAMTSL2 protein and an 8-protein soluble biomarker panel are highly associated with at-risk NASH and significant fibrosis; they exhibited superior diagnostic performance compared to standard of care fibrosis scores. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease worldwide. Diagnosing NAFLD and identifying fibrosis (scarring of the liver) currently requires a liver biopsy. Our study identified novel proteins found in the blood which may identify fibrosis without the need for a liver biopsy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Corey KE, Pitts R, Lai M, et al. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. J Hepatol. 2021. PMID: 34600973. doi:10.1016/j.jhep.2021.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。